Public Charity

BIOADVANCE CAPITAL

BIOADVANCE CAPITAL, of CONSHOHOCKEN, PA, is a Public Charity tracked in Imperigo's IRS 990 database. The 2025 filing shows $7.8M in revenue, $2.7M in expenses, $86.4M in total assets.

EIN: 460481876 CONSHOHOCKEN, PA Research Institutes & Public Policy Analysis NTEE: O05 Latest filing: 2025

Total Revenue$7.8M

Total Expenses$2.7M

Total Assets$86.4M

Grant Records0

Filing Years2021–2025

Mission

BIOADVANCE CAPITAL (FORMERLY BIOADVANCE) WAS ESTABLISHED IN 2001 AS ONE OF THE THREE LIFE SCIENCES GREENHOUSES FUNDED WITH A SHARE OF PENNSYLVANIA'S NATIONAL TOBACCO SETTLEMENT REVENUES TO PROMOTE HUMAN HEALTH BY SUPPORTING BIOMEDICAL INNOVATION IN SOUTHEASTERN PENNSYLVANIA. THE ORGANIZATION DEDICATED $25 MILLION OF THE ORIGINAL GRANT FUNDING TO PRE SEED AND EARLY STAGE INVESTMENTS TO HELP ADVANCE TECHNOLOGIES TO THE NEXT STAGE OF DEVELOPMENT. SINCE THE ORIGINAL GRANT FUNDING WAS EXPENDED, BIOADVANCE CAPITAL HAS CONTINUED TO SUPPORT EMERGING LIFE SCIENCES COMPANIES IN SOUTHEASTERN PENNSYLVANIA AND THE SURROUNDING MID ATLANTIC REGION, WITH A FOCUS ON TECHNOLOGIES THAT IMPROVE HUMAN HEALTH.

Where $100 goes at Bioadvance Capital

How Bioadvance Capital divides every $100 it spends, from its own Form 990 filings, averaged across 9 years.

$60 Programs the work itself

$40 Management running the organization

$0 Fundraising none reported

No fundraising costs are reported. That often means fundraising runs through a separate affiliated organization that files its own return.

Inside the $60 for programs

$60

Greenhouse program

All program spending

Source: Form 990 filings with the IRS, latest fiscal year 2025. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.

Officers & Directors

DIRECTOR Barbara S Schilberg

COO AND SECRETARY David Shin

DIRECTOR (EFF 6/13/25) Dr John Epstein

DIRECTOR (EFF 6/13/25) Dr Marie Lindner

ADVISORY PARTNER Frederick Jones

VP AND ASST SECRETARY Greg Harriman

Officer compensation and complete director data available with membership.

Financial Trends

Year	Revenue	Expenses	Assets
2025	$7.8M	$2.7M	$86.4M
2024	$7.1M	$2.6M	$81.1M
2023	$1.6M	$2.5M	$81.9M
2022	$2.5M	$2.3M	$73.1M
2021	$2.9M	$2.4M	$80.2M

Between 2021 and 2025, reported annual revenue grew from $2.9M to $7.8M (+166%), with total assets most recently reported at $86.4M.

Interactive year-over-year charts and full filing details available with membership.

See the full picture for BIOADVANCE CAPITAL

Complete financials, all 0 grant records, officer compensation, year-over-year trend charts, a geographic grant map, and data exports — across 880,000+ organizations.

Full Financial History Complete Grant Activity Officer Compensation Year-over-Year Charts Geographic Grant Map Data Exports